CN Patent

CN106943355B — 药物组合物

Assigned to Novartis AG · Expires 2020-09-01 · 6y expired

What this patent protects

本发明涉及一种经口给予的药物组合物，其包含4‑氨基‑5‑氟‑3‑[6‑(4‑甲基哌嗪‑1‑基)‑1H‑苯并咪唑‑2‑基]‑1H‑喹啉‑2‑酮单乳酸盐单水合物，15％至70重量％的填充剂，少于15重量％的崩解剂，0.1％至10重量％的助流剂及/或润滑剂，其中所述重量的量是根据该组合物的总重量计算的。

USPTO Abstract

本发明涉及一种经口给予的药物组合物，其包含4‑氨基‑5‑氟‑3‑[6‑(4‑甲基哌嗪‑1‑基)‑1H‑苯并咪唑‑2‑基]‑1H‑喹啉‑2‑酮单乳酸盐单水合物，15％至70重量％的填充剂，少于15重量％的崩解剂，0.1％至10重量％的助流剂及/或润滑剂，其中所述重量的量是根据该组合物的总重量计算的。

Drugs covered by this patent

Patent Metadata

Patent number
CN106943355B
Jurisdiction
CN
Classification
—
Expires
2020-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.